Citi downgraded Pactiv Evergreen (PTVE) to Neutral from Buy with a price target of $18, up from $13. The firm sees limited upside to the shares following the announced combination with Novolex. Pactiv shares traded up 18% to close at $17.36 Monday, implying a reasonably tight spread on the deal, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue